Lopinavir News and Research

RSS
Will 'old faithful' tuberculosis BCG vaccine work against COVID?

Will 'old faithful' tuberculosis BCG vaccine work against COVID?

Critical guidance to identify COVID-19 patients at risk of drug-induced sudden cardiac death

Critical guidance to identify COVID-19 patients at risk of drug-induced sudden cardiac death

Projects to develop COVID-19 vaccines receive U.K. gov’t funding

Projects to develop COVID-19 vaccines receive U.K. gov’t funding

Huge WHO trial of COVID-19 therapies begins

Huge WHO trial of COVID-19 therapies begins

First patients enrolled in new clinical trial to evaluate potential COVID-19 treatments

First patients enrolled in new clinical trial to evaluate potential COVID-19 treatments

Lopinavir and ritonavir drug combo tested in severe COVID-19

Lopinavir and ritonavir drug combo tested in severe COVID-19

The changing face of the COVID-19 epidemic

The changing face of the COVID-19 epidemic

To fight Chinese outbreak, doctors deploy drugs targeting HIV, malaria and Ebola

To fight Chinese outbreak, doctors deploy drugs targeting HIV, malaria and Ebola

New trial examines use of nanotechnology to improve delivery of drugs to HIV patients

New trial examines use of nanotechnology to improve delivery of drugs to HIV patients

New study proves that 'super-boosting' approach may help treat children co-infected with TB and HIV

New study proves that 'super-boosting' approach may help treat children co-infected with TB and HIV

New research examines use of nanotechnology to improve delivery of drugs to HIV patients

New research examines use of nanotechnology to improve delivery of drugs to HIV patients

Hitchhiking of drugs on incorrect targets can cause adverse side effects

Hitchhiking of drugs on incorrect targets can cause adverse side effects

MPP signs licensing agreement with AbbVie to address future demands for HIV treatment in Africa

MPP signs licensing agreement with AbbVie to address future demands for HIV treatment in Africa

XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

MPP collaborates with University of Liverpool to accelerate development of HIV nanomedicines

MPP collaborates with University of Liverpool to accelerate development of HIV nanomedicines

12 months of liquid formula HIV drugs protect breastfeeding babies against HIV infection

12 months of liquid formula HIV drugs protect breastfeeding babies against HIV infection

Study evaluates effectiveness of antiretroviral treatment in HIV-infected children

Study evaluates effectiveness of antiretroviral treatment in HIV-infected children

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Tentative FDA approval of lopinavir/ritonavir oral pellet formulation closes treatment gap for children with HIV

Tentative FDA approval of lopinavir/ritonavir oral pellet formulation closes treatment gap for children with HIV

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer